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In this issue of Cell Stem Cell, Belema-Bedada et al. (2008) describe a novel mechanism by which bone
marrow-derived adult mesenchymal stem cells migrate to sites of damaged heart tissue. This process is de-
pendent on the intracellular adaptor molecule FROUNT, which interacts with the chemokine receptor CCR2.Coronary artery disease and cardiomyop-
athy are major causes of mortality and
morbidity in western countries. Cardio-
myopathy and its clinical syndrome of
cardiac failure occur as the end product
of pathological myocardial remodeling,
a process that can be triggered by various
types of insult and that is underpinned by
progressive loss of cardiomyocytes. De-
spite the recent discovery of cardiac resi-
dent progenitor/stem cells (Beltrami et al.,
2003), the heart has only a limited capac-
ity for self-regeneration, and conventional
pharmacological and device-based ther-
apies for coronary ischemia and heart
failure do little to address this problem.
Consequently, novel treatment strategies
have been pursued and great stock has
been placed on the field of cardiovascular
regeneration, fuelling the emergence of
gene and cell-based therapies.
Cellular therapy for cardiovascular dis-
ease has developed rapidly on the back
of a large number of preclinical animal tri-
als and a steady output of human clinical
trials. A variety of embryonic and adult-
derived cell types have been investigated
for their capacity to mediate cardiac
and vascular repair, including unfraction-
ated bone marrow cells and mononu-
clear cells, mesenchymal stem cells
(MSCs), endothelial progenitor cells, skel-
etal myoblasts, cardiac progenitor cells,
and embryonic stem cells (Laflamme
and Murry, 2005). In each case, there is
ongoing controversy surrounding various
issues such as optimal cell type, dose
and mode of administration, and the po-
tential mechanism of action of the trans-
planted cells.
The adequate delivery of cells to the
heart and in turn sufficient retention andengraftment of cells within the myocar-
dium are crucial prerequisites to ensure
successful cell-based cardiac repair.
Cell therapy can be administered by direct
injection into the heart, by vascular infu-
sion (coronary vessels or peripheral veins)
or bymobilizing endogenous cells into the
circulation via growth factor treatment.
Irrespective of the technique employed,
cardiac engraftment has been repeatedly
disappointing, providing a significant bar-
rier to optimal tissue repair/regeneration.
Moreover, noncardiac entrapment of cells
may be particularly prevalent after sys-
temic delivery, with uncertain ramifica-
tions (Freyman et al., 2006).
The capacity of MSCs (also referred to
as mesenchymal or bone marrow stromal
cells) to migrate through the circulation
to other tissues has been controversial,
although there is growing evidence that
endogenous mobilization may occur in
response to hypoxic tissue insult and
that infused culture-expanded MSCs
preferentially home to areas of tissue
damage. This finding has led to increasing
research efforts to identify the potential
mechanisms that may mediate these pro-
cesses under both physiological and
pathological conditions.
The study by Belema-Bedada and col-
leagues (Belema-Bedada et al., 2008) de-
scribes a novel mechanism by which
prospectively isolated bone marrow-de-
rived adult mesenchymal stem cells
(BM-MASCs) home to the bone marrow
and migrate to sites of damaged heart tis-
sue following infusion. BM-MASCs exhibit
important hallmarks of stem cells in that
they possess the capacity for differentia-
tion into multiple skeletal tissues and
undergo self-renewal, as determined byCell Stemtheir high proliferative potential (>25 pas-
sages) and their ability to be serially trans-
planted into recipient mice. While two
subtypes of MASCs are described based
on their phenotype at isolation, MASC-1
(CD34/Sca-1High BM cells) and MASC-2
(CD34+/Sca-1Mod BM cells), there appear
to be few or no substantive biological
differences between the two populations
in relation to their migratory properties.
These findings are consistent with other
studies that have reported similar func-
tional properties between different ex vivo-
expanded MSC preparations regardless
of the heterogeneity of these cell popula-
tions and modes of isolation.
Using a microarray-based approach,
the authors identified a number of candi-
date molecules expressed by ex vivo-ex-
panded MASCs known to have roles in
cellular migration and homing, including
the chemokine receptors CCR10 and
CCR2. These findings are in keeping
with previous studies showing that ex
vivo-expanded MSCs express a variety
of functional CC chemokine receptors
(CCR1, CCR2, CCR5, and CCR7-9) and
CXC chemokine receptors (CXCR1,
CXCR4, CXCR3, CXCR5, and CXCR6)
(Honczarenko et al., 2006; Kortesidis
et al., 2005; Ringe et al., 2007; Wynn
et al., 2004) that facilitate MSC survival
andmigration in the presence of appropri-
ate chemokine ligands.
CCR2 belongs to a family of heterotri-
meric G protein-coupled receptors that
mediate their cellular responses via phos-
pholipase C isoforms, phosphoinositide
3-kinase, and c-Src family tyrosine
kinases (Moser et al., 2004). Although
CCR2 has three known ligands (CCL2,
CCL7, and CCL12), CCL2/MCP-1 hasCell 2, June 2008 ª2008 Elsevier Inc. 513
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ied in relation to cardiac tissue
repair. To examine the role of
CCR2-CCL2 interactions in the
migration ofMASCs to the heart,
the authors used a transgenic
mouse model (MyHC-MCP-1
animals) in which CCL2/MCP-1
was expressed at high levels in
cardiac tissue under the control
of the myosin heavy-chain pro-
moter. While CCL2/MCP-1 is
expressed endogenously by a
variety of cells, the heightened
expression of this chemokine in
cardiac tissues led to apreferen-
tial CCR2-dependent migration
of MASCs to the heart. This
migration was further regula-
ted by the adaptor molecule
FROUNT/Nup85. FROUNT, a
novel activator of chemokine
signaling, was required for the
polarization, cytoskeletal reor-
ganization, and clustering of
CCR2 on theMASCcell surface.
Furthermore, expression of
a dominant-negative isoform
of FROUNT (DN-FROUNT) in
MASCs abrogated their homing
to injured myocardium in a
nontransgenic mouse model of
ischemic-reperfusion injury.
These findings suggest that
FROUNT-mediated signaling is
a limiting step in the homingpro-
cess that cannot be easily by-
passed by alternative signaling
events. The study by Belema-
Bedada et al. (2008) contrasts an earlier
publication by Ringe et al. (2007), which
showed that, while human MSC express
CCR2, they do notmigrate upon stimulation
with CCL2. While this difference may be at-
tributable to species differences or subtle
differences in cell populations, a reason for
this discrepancy awaits further study. These
findings suggest that other important fac-
tors, besides MCP-1/CCL2, are most likely
involved in the migration of human MSC.
In accord with this notion, previous stud-
ies have implicated either CCR1, CCR2,
or CCR5 receptors in the homing of
MSC in response to elevated levels of
their common chemokine ligand, MCP-
3/CCL7, following myocardial infarction
(Schenk et al., 2007). Furthermore, other
studies have identified that CXCL12
(stromal-derived factor-1, SDF-1),
granulocyte-colony stimulating factor
(G-CSF), stem cell factor (SCF), interleu-
kin-8 (IL-8), and vascular endothelial
growth factor (VEGF) are elevated
following myocardial infarction. Collec-
tively, these studies raise the question as
to the relative contribution that each of
these receptor-ligand pairs play in the
recruitment of cells to the injured myocar-
dium.
While ex vivo-expanded MSC popula-
tions can readily develop into various
skeletal tissues with varying efficiencies,
their low incidence of conversion into
functional cardiomyocytes, either through
transdifferentiation or fusion, cannot ex-
plain the improvements in heart function
observed in animal models of myocardial
infarction. The paper by Be-
lema-Bedada et al. (2008) sug-
gests that, following homing to
cardiac tissue, MASC-medi-
ated tissue repair may occur,
in part, via their expression of
CXCL12. The secretion of
CXCL12 and other factors by
MASC may act in a paracrine
fashion to regulate inflamma-
tory responses, blood vessel
formation, and the recruitment
of circulating stem/progenitor
cells or endogenous cardio-
myocyte progenitor cells (Fig-
ure 1). While these questions
await further study, a greater
understanding of the precise
molecular mechanisms con-
trolling MSC recruitment may
facilitate the development of
therapeutic modalities de-
signed to specifically promote
the homing of MSCs to sites
of tissue injury.
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Figure 1. Model for the Homing of BM-MASCs to the Heart by
FROUNT-Mediated Clustering of CCR2
A subset of BM-MASCs express CCR2. Binding of MCP-1/CCL2 to CCR2
leads to receptor activation and recruitment of FROUNT, which clusters
with CCR2 at the plasma membrane. Clusters of CCR2/FROUNT distrib-
ute asymmetrically at either side of the nucleus and activate PI(3)K to
reorganize actin filaments, polarizing the cell and leading to formation of
lamellipodia protrusions. MASCs that home to and engraft in the heart
express SDF-1, which may give rise to local collections of MASC-derived
cells and to the retention of additional ‘‘recruited bonemarrow-derived cir-
culating cells’’ (RBCCs) (Figure S10, Belema-Bedada et al. [2008], in this
issue of Cell Stem Cell).514 Cell Stem Cell 2, June 2008 ª2008 Elsevier Inc.
